Antacids and Acidity Tablets — Can Block Your Cancer Drug

Not without asking your oncology team first. Digene and Gelusil contain antacids that raise stomach pH, which can reduce the absorption of many targeted therapy tablets. Whether a timing gap makes it safe depends on your specific drug — for some, a few hours of separation reduces the interaction; for others, even short-acting antacids are to be avoided. Call your team before the next dose rather than assuming it is fine.

Omeprazole and pantoprazole suppress stomach acid for many hours, often throughout the entire day, which can significantly reduce how much of your targeted therapy tablet reaches your bloodstream. ESMO and NCCN guidance highlights proton pump inhibitors as a significant concern for a number of oral targeted therapies. Tell your oncologist that you are on a PPI — they may be able to suggest a safer alternative for managing your acidity, or adjust how your cancer drug is taken.

For short-acting antacid gels like Gelusil or Digene, separating doses by several hours reduces — but may not eliminate — the interaction for some targeted therapies. Your oncologist or clinical pharmacist can tell you whether this applies to your drug and what the minimum gap should be. This approach does not work for proton pump inhibitors or H2 blockers, which alter stomach acid for many hours regardless of timing. Never assume a timing workaround is safe without checking for your specific drug.

Tell your oncology team rather than managing it yourself. Acidity and reflux are recognised side effects of some targeted therapies, and your team needs to know it is happening. They can recommend something that manages the symptom without interfering with your cancer drug. What is safe depends on which targeted therapy you are on. Taking the first antacid you find at home or a pharmacy risks an interaction that affects how well your treatment is working.

CYP3A4 is a liver enzyme that breaks down many drugs, including a number of targeted therapies. When a medicine slows this enzyme, your cancer drug can build up to higher-than-intended levels, increasing side effects. When a medicine speeds it up, the drug clears too quickly and may not work well. Most common antacid gels and PPIs mainly affect stomach pH rather than CYP3A4 — but cimetidine, an older acidity medicine still found in some households, is a known CYP3A4 inhibitor. This is a separate concern from absorption, and one more reason to tell your team about everything you take.

The pH-dependent absorption problem is most relevant to oral targeted therapy tablets, because these depend on stomach acidity to dissolve. Chemotherapy is usually given by intravenous drip, which bypasses the stomach entirely, so this specific mechanism does not apply in the same way. Some oral chemotherapy agents can also be affected by stomach pH, so it is still worth mentioning any acidity medicines to your team regardless of what type of treatment you are on.

Tell your oncology team at your next appointment — or sooner if the next appointment is more than a few days away. They may want to review how your treatment is responding. Do not stop the antacid abruptly without asking, and do not stop your cancer drug. How significant the interaction has been depends on which medicines were involved and which targeted therapy you are on. Your team can only help once they know what has been happening.

Tell both the prescribing doctor and your oncology team before changing anything. This is a common situation — stomach protection is often prescribed alongside pain medicines or anti-inflammatory drugs. Your oncology team can advise whether an alternative approach to stomach protection is possible, or whether your cancer drug can be managed differently. Neither doctor should change a prescription without the other knowing, and sharing this information yourself is the most reliable way to make sure both sides are aware.